Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study - Report - MDSpire

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study

  • By

  • Jinhan Chen

  • Qian Xu

  • Bozhou Wang

  • Huiwen Sun

  • Qijin Shu

  • June 4, 2026

  • 0 min

Share

Clinical Report: Cutaneous Reactions on Hands and Feet Linked to VEGFR-TKIs

Overview

{'add': 'Specify the specific agents with notable differences in signal strength.'}

Background

{'add': 'More details on the impact of HFSR on treatment adherence and quality of life.'}

Data Highlights

{'add': 'Include all relevant VEGFR-TKIs analyzed in the study.'}

Key Findings

{'add': 'Clarify the significance of the findings and total number of VEGFR-TKIs analyzed.'}

Clinical Implications

{'add': 'Suggest specific proactive management strategies beyond topical treatments.'}

Conclusion

{'add': 'Reiterate the importance of individualized monitoring and management strategies.'}

Related Resources & Content

  1. The ASCO Post, 2012 -- Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome
  2. Frontiers in Medicine, 2026 -- Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study
  3. The ASCO Post, 2012 -- VEGFR Tyrosine Kinase Inhibitors Linked to Increased Risk of Fatal Adverse Events
  4. Drug Safety — Analysis of Thromboembolic Event Reporting Associated with JAK Inhibitors: Insights from the FAERS Database (2010–2019)
  5. ESMO Guidelines on Management of Skin Toxicities from MKIs
  6. Diagnosis and treatment of cutaneous adverse effects of targeted therapy
  7. DailyMed - STIVARGA- regorafenib tablet, film coated
  8. Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib - PMC
  9. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma - PMC
  10. Sorafenib in Advanced Hepatocellular Carcinoma | New England Journal of Medicine
  11. Frontiers | Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A FAERS-based pharmacovigilance study
  12. Frontiers | Construction of a management and prevention program for targeted therapy-induced hand-foot skin reaction
  13. Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies - PMC
  14. Artificial intelligence system for predicting hand-foot skin reaction induced by vascular endothelial growth factor receptor inhibitors - PubMed

Original Source(s)

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study

  • by Jinhan Chen, Qian Xu, Bozhou Wang, Huiwen Sun, Qijin Shu

  • June 4, 2026

Related Content

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination